BiotechTube

Ciprofloxacin (Cipro, BAYQ3939)

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pseudomonas Infection

Conditions

Pseudomonas Infection

Trial Timeline

Jul 1, 2009 → Oct 1, 2010

NCT ID
NCT00910351

About Ciprofloxacin (Cipro, BAYQ3939)

Ciprofloxacin (Cipro, BAYQ3939) is a phase 1 stage product being developed by Bayer for Pseudomonas Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00910351. Target conditions include Pseudomonas Infection.

What happened to similar drugs?

1 of 5 similar drugs in Pseudomonas Infection were approved

Approved (1) Terminated (2) Active (3)
✅TIS or TIPNovartisApproved
🔄tobramycin + tobramycinNovartisPhase 3
🔄Tobramycin inhalation powderNovartisPhase 3
❌AZLI + PlaceboGilead SciencesPhase 3
🔄Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. + Tobramycin inhalation solution using a PARI LC® Plus nebulizer.InsmedPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT01561794Phase 3Completed
NCT00910351Phase 1Completed

Competing Products

8 competing products in Pseudomonas Infection

See all competitors
ProductCompanyStageHype Score
AZD0292AstraZenecaPhase 2
42
tobramycin + tobramycinNovartisPhase 3
40
Tobramycin inhalation powderNovartisPhase 3
40
TIS or TIPNovartisApproved
35
AZLI + PlaceboGilead SciencesPhase 3
32
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. + Tobramycin inhalation solution using a PARI LC® Plus nebulizer.InsmedPhase 3
37
TOBI® PODHALER® + TOBI® + Bethkis® + Cayston®ViatrisPre-clinical
23
IC43 + PlaceboValneva SEPhase 2/3
32